In chronic myelogenous leukemia (CML) cells, AS inhibits self-ubiquitination of c-CBL by binding to its RING domain, hence enhancing the ability of c-CBL to degrade its target proteins including BCR-ABL6. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.